Exchange: NASDAQ·Updated 07:57 PM EDT
News
all
press releases
Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates
Precigen (PGEN) delivered earnings and revenue surprises of +350.00% and +97.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +42.90% and +11.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Geron (GERN) Grants Inducement Stock Options to New Employees
Geron (GERN) Grants Inducement Stock Options to New Employees...
Yahoo! Finance: News
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...
PR Newswire
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Geron Q1 Earnings Call Highlights
Geron (NASDAQ:GERN) reported first-quarter 2026 net revenue of $61.8 million, up 31% year-over-year and 8% quarter-over-quarter, as the company continued to scale commercialization of Rytelo in the...
MarketBeat
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +60.00% and +2.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Geron (NASDAQ:GERN) Stock Price Passes Above 200-Day Moving Average - What's Next?
Geron (NASDAQ:GERN) Shares Pass Above 200 Day Moving Average - Here's What Happened...
MarketBeat

Advertisement|Remove ads.